Wednesday, September 20, 2017 5:12:58 PM
And the ITUS Paid Stock Promotion continues today
Company: ITUS Corporation ( ITUS )
End of Day: $ Close: 1.930 Volume: 14,058,319
$ Intraday High: 2.700 % Change: 0.526
$ Change: 0.010 $ Volume: 27,133,962
$ Open: 1.870
$ Previous Close: 1.920
3 Month: $ High / Low 2.700 / 0.600 Volume 3m avg: 968,499
Promoter: OTC Tip Reporter
Compensation: To date we have been compensated One Hundred Thousand dollars USD to profile ITUS. Please be advised THAT we have been compensated an additional Thirty-Five Thousand dollars USD by a non-affiliated third party for marketing exposure which has since expired.
Date: 9/20/2017 View:View MessageShare:Post to Facebook
Share to Twitter
Company: ITUS Corporation ( ITUS )
End of Day: $ Close: 1.930 Volume: 14,058,319
$ Intraday High: 2.700 % Change: 0.526
$ Change: 0.010 $ Volume: 27,133,962
$ Open: 1.870
$ Previous Close: 1.920
3 Month: $ High / Low 2.700 / 0.600 Volume 3m avg: 968,499
Promoter: Penny Stock Prophet
Compensation: None Listed or Image Compensation
Date: 9/20/2017 View:View MessageShare:Post to Facebook
Share to Twitter
Company: ITUS Corporation ( ITUS )
End of Day: $ Close: 1.920 Volume: 11,542,804
$ Intraday High: 1.940 % Change: 50.000
$ Change: 0.640 $ Volume: 22,162,184
$ Open: 1.270
$ Previous Close: 1.280
3 Month: $ High / Low 1.940 / 0.600 Volume 3m avg: 753,179
Promoter: Penny Stock Prophet
Compensation: None Listed or Image Compensation
Date: 9/19/2017 View:View MessageShare:Post to Facebook
Share to Twitter
Company: ITUS Corporation ( ITUS )
End of Day: $ Close: 1.920 Volume: 11,409,083
$ Intraday High: 1.940 % Change: 50.000
$ Change: 0.640 $ Volume: 21,905,439
$ Open: 1.270
$ Previous Close: 1.280
3 Month: $ High / Low 1.940 / 0.600 Volume 3m avg: 751,122
Promoter: OTC Tip Reporter
Compensation: To date we have been compensated One Hundred Thousand dollars USD to profile ITUS. Please be advised THAT we have been compensated an additional Thirty-Five Thousand dollars USD by a non-affiliated third party for marketing exposure which has since expired.
Date: 9/19/2017 View:View MessageShare:Post to Facebook
Share to Twitter
Company: ITUS Corporation ( ITUS )
End of Day: $ Close: 1.280 Volume: 22,703,071
$ Intraday High: 1.610 % Change: 85.507
$ Change: 0.590 $ Volume: 29,059,931
$ Open: 0.700
$ Previous Close: 0.690
3 Month: $ High / Low 1.610 / 0.600 Volume 3m avg: 582,970
Promoter: OTC Tip Reporter
Compensation: To date we have been compensated One Hundred Thousand dollars USD to profile ITUS. Please be advised THAT we have been compensated an additional Thirty-Five Thousand dollars USD by a non-affiliated third party for marketing exposure which has since expired.
Date: 9/18/2017 View:View MessageShare:Post to Facebook
Share to Twitter
Company: ITUS Corporation ( ITUS )
End of Day: $ Close: 1.280 Volume: 22,703,071
$ Intraday High: 1.610 % Change: 85.507
$ Change: 0.590 $ Volume: 29,059,931
$ Open: 0.700
$ Previous Close: 0.690
3 Month: $ High / Low 1.610 / 0.600 Volume 3m avg: 582,970
Promoter: Penny Stock Prophet
Compensation: None Listed or Image Compensation
Date: 9/18/2017 View:View MessageShare:Post to Facebook
Share to Twitter
Company: ITUS Corporation ( ITUS )
End of Day: $ Close: 0.690 Volume: 209,959
$ Intraday High: 0.763 % Change: -5.479
$ Change: -0.040 $ Volume: 144,872
$ Open: 0.750
$ Previous Close: 0.730
3 Month: $ High / Low 1.320 / 0.600 Volume 3m avg: 225,631
Promoter: Investor Ideas
Compensation: Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers.
Date: 9/15/2017 View:View MessageShare:Post to Facebook
Share to Twitter
Company: ITUS Corporation ( ITUS )
End of Day: $ Close: 1.930 Volume: 14,058,319
$ Intraday High: 2.700 % Change: 0.526
$ Change: 0.010 $ Volume: 27,133,962
$ Open: 1.870
$ Previous Close: 1.920
3 Month: $ High / Low 2.700 / 0.600 Volume 3m avg: 968,499
Promoter: OTC Tip Reporter
Compensation: To date we have been compensated One Hundred Thousand dollars USD to profile ITUS. Please be advised THAT we have been compensated an additional Thirty-Five Thousand dollars USD by a non-affiliated third party for marketing exposure which has since expired.
Date: 9/20/2017 View:View MessageShare:Post to Facebook
Share to Twitter
Company: ITUS Corporation ( ITUS )
End of Day: $ Close: 1.930 Volume: 14,058,319
$ Intraday High: 2.700 % Change: 0.526
$ Change: 0.010 $ Volume: 27,133,962
$ Open: 1.870
$ Previous Close: 1.920
3 Month: $ High / Low 2.700 / 0.600 Volume 3m avg: 968,499
Promoter: Penny Stock Prophet
Compensation: None Listed or Image Compensation
Date: 9/20/2017 View:View MessageShare:Post to Facebook
Share to Twitter
Company: ITUS Corporation ( ITUS )
End of Day: $ Close: 1.920 Volume: 11,542,804
$ Intraday High: 1.940 % Change: 50.000
$ Change: 0.640 $ Volume: 22,162,184
$ Open: 1.270
$ Previous Close: 1.280
3 Month: $ High / Low 1.940 / 0.600 Volume 3m avg: 753,179
Promoter: Penny Stock Prophet
Compensation: None Listed or Image Compensation
Date: 9/19/2017 View:View MessageShare:Post to Facebook
Share to Twitter
Company: ITUS Corporation ( ITUS )
End of Day: $ Close: 1.920 Volume: 11,409,083
$ Intraday High: 1.940 % Change: 50.000
$ Change: 0.640 $ Volume: 21,905,439
$ Open: 1.270
$ Previous Close: 1.280
3 Month: $ High / Low 1.940 / 0.600 Volume 3m avg: 751,122
Promoter: OTC Tip Reporter
Compensation: To date we have been compensated One Hundred Thousand dollars USD to profile ITUS. Please be advised THAT we have been compensated an additional Thirty-Five Thousand dollars USD by a non-affiliated third party for marketing exposure which has since expired.
Date: 9/19/2017 View:View MessageShare:Post to Facebook
Share to Twitter
Company: ITUS Corporation ( ITUS )
End of Day: $ Close: 1.280 Volume: 22,703,071
$ Intraday High: 1.610 % Change: 85.507
$ Change: 0.590 $ Volume: 29,059,931
$ Open: 0.700
$ Previous Close: 0.690
3 Month: $ High / Low 1.610 / 0.600 Volume 3m avg: 582,970
Promoter: OTC Tip Reporter
Compensation: To date we have been compensated One Hundred Thousand dollars USD to profile ITUS. Please be advised THAT we have been compensated an additional Thirty-Five Thousand dollars USD by a non-affiliated third party for marketing exposure which has since expired.
Date: 9/18/2017 View:View MessageShare:Post to Facebook
Share to Twitter
Company: ITUS Corporation ( ITUS )
End of Day: $ Close: 1.280 Volume: 22,703,071
$ Intraday High: 1.610 % Change: 85.507
$ Change: 0.590 $ Volume: 29,059,931
$ Open: 0.700
$ Previous Close: 0.690
3 Month: $ High / Low 1.610 / 0.600 Volume 3m avg: 582,970
Promoter: Penny Stock Prophet
Compensation: None Listed or Image Compensation
Date: 9/18/2017 View:View MessageShare:Post to Facebook
Share to Twitter
Company: ITUS Corporation ( ITUS )
End of Day: $ Close: 0.690 Volume: 209,959
$ Intraday High: 0.763 % Change: -5.479
$ Change: -0.040 $ Volume: 144,872
$ Open: 0.750
$ Previous Close: 0.730
3 Month: $ High / Low 1.320 / 0.600 Volume 3m avg: 225,631
Promoter: Investor Ideas
Compensation: Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers.
Date: 9/15/2017 View:View MessageShare:Post to Facebook
Share to Twitter
Recent ANIX News
- Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance • PR Newswire (US) • 06/01/2026 01:00:00 PM
- /C O R R E C T I O N -- Anixa Biosciences, Inc./ • PR Newswire (US) • 05/11/2026 03:48:00 PM
- Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy • PR Newswire (US) • 05/11/2026 12:55:00 PM
- Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV • PR Newswire (US) • 05/01/2026 01:15:00 PM
- Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology • PR Newswire (US) • 04/29/2026 01:10:00 PM
- Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting • PR Newswire (US) • 04/22/2026 12:45:00 PM
- Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026 • PR Newswire (US) • 04/09/2026 01:05:00 PM
- Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026 • PR Newswire (US) • 04/07/2026 12:55:00 PM
- Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs • PR Newswire (US) • 04/06/2026 01:10:00 PM
- Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing • PR Newswire (US) • 04/01/2026 12:50:00 PM
- Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer • PR Newswire (US) • 03/30/2026 01:05:00 PM
- Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast • PR Newswire (US) • 03/12/2026 02:38:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/09/2026 08:16:07 PM
- Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology • PR Newswire (US) • 03/09/2026 12:30:00 PM
- Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress • PR Newswire (US) • 03/02/2026 02:10:00 PM
- Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat • PR Newswire (US) • 02/23/2026 01:55:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 01:02:40 PM
- Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation • PR Newswire (US) • 02/09/2026 01:00:00 PM
- Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization • PR Newswire (US) • 02/02/2026 02:00:00 PM
- Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology • PR Newswire (US) • 01/27/2026 01:30:00 PM
- Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic • PR Newswire (US) • 12/15/2025 01:45:00 PM
- Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants • PR Newswire (US) • 12/11/2025 11:02:00 PM
- Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025 • PR Newswire (US) • 12/10/2025 02:00:00 PM
- Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization • PR Newswire (US) • 11/17/2025 01:15:00 PM
- Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s • PR Newswire (US) • 11/12/2025 02:00:00 PM
